1C84 Chapman, Andrew - Thomas Jefferson University - Thomas Jefferson University
Dr. Chapman

Andrew Chapman, DO, FACP

Contact Dr. Chapman

925 Chestnut Street
Suite 220A
Philadelphia, PA 19107

(215) 923-5676

Most Recent Peer-reviewed Publications

  1. Evaluation of a pharmacist-led medication assessment used to identify prevalence of and associations with polypharmacy and potentially inappropriate medication use among ambulatory senior adults with cancer
  2. Silver oncologic tsunami: Quality issues in the senior adult oncology population
  3. Predictors of chemotherapy dose reduction at first cycle in patients age 65years and older with solid tumors
  4. A pharmacist-led medication assessment used to determine a more precise estimation of the prevalence of complementary and alternative medication (CAM) use among ambulatory senior adults with cancer
  5. Randomized phase II trial of irinotecan/docetaxel or irinotecan/docetaxel plus cetuximab for metastatic pancreatic cancer: An eastern cooperative oncology group study
  6. Development of a comprehensive multidisciplinary geriatric oncology center, the Thomas Jefferson university experience
  7. Senior adult oncology: Three cases of advanced cancer in patients of advanced age
  8. Metastatic unknown primary tumor presenting in pregnancy as multiple cerebral infarcts
  9. Phase II: Trial of twice weekly amifostine in patients with non-small cell lung cancer treated with chemoradiotherapy
  10. Preliminary report on reduction of esophagitis by amifostine in patients with non-small-cell lung cancer treated with chemoradiotherapy
  11. Increase of βIII- and βIVa-tubulin isotypes in human prostate carcinoma cells as a result of estramustine resistance
  12. Phase I study of paclitaxel and estramustine: Prel 0447 iminary activity in hormone-refractory prostate cancer
  13. Multiple drug resistance: Biologic basis and clinical significance in renal-cell carcinoma
  14. P-glycoprotein binding and modulation of the multidrug-resistant phenotype by estramustine